Skip to main content
. 2013 Jan 1;2(1):e23033. doi: 10.4161/onci.23033

graphic file with name onci-2-e23033-g4.jpg

Figure 4. Tetramer-based assessments of T-cell immune responses after therapy. (A and B) Cytoflurometric analyses of two HLA-A2+ patients with malignant melanoma on schedule B, 0.1 mg/Kg CP-870,893 (A), and schedule B, 0.2 mg/Kg CP-870,893 (B). The percentages of tetramer-positive CD8+ T cells are shown for each gate.